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Abstract
Background: To explore the impact of patient-characteristics and relevant comorbidities on treatment continuation
rates, effectiveness, and satisfaction in patients with erectile dysfunction (ED) who started or switched to tadalafil
5 mg once daily (TAD-OaD) at baseline.
Methods: In the EDATE observational study, phosphodiesterase-type-5 (PDE5)-inhibitor pretreated or naïve ED
patients who started or switched to TAD-OaD were prospectively followed for 6 months. Time to discontinuation of
TAD-OaD was estimated using the Kaplan-Meier product-limit method at Months 2, 4, and 6 in subgroups stratified
by age (18 − 65 years and >65 years), PDE5-inhibitor pretreatment, ED-severity (mild, moderate, severe), and presence
or absence of relevant comorbidities (BPH, diabetes, CVD, hypertension, dyslipidemia). LSmean change from baseline in
International Index of Erectile Function (IIEF) and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) scores
and associated 95 % CIs were assessed using a mixed-model for repeated measures. Visit, ED etiology, and subgroups
were included as fixed-effects.
Results: Overall, 778 patients received prescriptions for initiating or switching to TAD-OaD at baseline. At
Month 2, >90 % of patients remained on TAD-OaD, except those aged >65 years (86.7 %) and patients with
severe ED (89.0 %). More than 80 % of patients in all subgroups, except those aged >65 years (75.0 %),
continued TAD-OaD at Month 6. There was a significant LSmean negative effect on IIEF- EF domain-score
improvement for BPH (LSmean effect [95 % CI]: −2.77 [−4.98, −0.55], p = 0.014), previous PDE5-inhibitor treatment
(−2.13 [−3.33,-0.94], p < 0.001), and mild vs moderate ED (-2.00 [−3.54,-0.46], p = 0.011); the latter possibly linked with
a bigger treatment-effect in those with more severe ED at baseline. The LSmean effect on change in IIEF-EF was
significantly positive for diabetes (2.28 [0.64,3.92], p = 0.007), most likely because those with diabetes had more severe
ED at baseline. For all other parameters, no statistically significant LSmean effects in IIEF-EF changes were observed.
No comorbidity or baseline-characteristic except age (18 − 65 years vs >65 years: 11.25 [2.96,19.54], p = 0.008)
affected changes in EDITS.
Conclusions: Under routine clinical conditions, treatment continuation rate or satisfaction does not seem to be
significantly affected by the presence of comorbidities in men who choose ED-treatment with TAD-OaD. The magnitude
of treatment effectiveness was affected by certain baseline characteristics and comorbid conditions.
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Background
Men with erectile dysfunction (ED) have several comorbid
conditions such as cardiovascular disease (CVD) and asso-
ciated risk factors including diabetes, hypertension, dyslip-
idemia, smoking, obesity, sedentary lifestyle, and others
such as depression, premature ejaculation, lower urinary
tract symptoms (LUTS) secondary to benign prostatic
hyperplasia (BPH), and overactive bladder [1–4]. In the
Men’s Attitudes to Life Events and Sexuality (MALES)
study, 64 % of the men reported having at least 1 comor-
bid condition including hypertension (36 %), dyslipidemia
(29 %), depression (25 %), CVD (17 %), and diabetes
(14 %) [1].
Given these prevalence rates of comorbidities in men
with ED, it is important to choose an appropriate treat-
ment that maintains its efficacy and tolerability in the
presence of the comorbidities [5]. Oral phosphodiester-
ase type 5 (PDE5) inhibitors including avanafil, sildenafil,
tadalafil, and vardenafil are proven to be safe and effect-
ive for managing ED [6–14]. Furthermore, these drugs
have demonstrated efficacy in men with ED who have
comorbid cardiovascular risk factors including hyperten-
sion, dyslipidemia, and/or diabetes [5], and tadalafil once
daily (OaD) has shown efficacy in the treatment of BPH/
LUTS [15–17].
It has been suggested that appropriate treatment of
concomitant ED may help in improving the adherence
and management of associated comorbidities, which
may eventually decrease healthcare costs and improve
the overall health of the affected men [18]. However,
some pharmacological drugs used for treating these co-
morbid conditions have sexual side effects. For example,
antihypertensive drugs such as thiazide diuretics increase
the risk of ED; 5α-reductase inhibitors, used for treating
LUTS linked to symptomatic BPH, are associated with
sexual disorders; and α-blockers tamsusolin and silodo-
sin, used for treating BPH, are frequently responsible for
ejaculatory disorders like anejaculation and reduced
ejaculate volume [19]. This further underscores the
significance of choosing an efficacious medication for
treating ED in these subpopulations, if required.
The EDATE study was the first multinational, observa-
tional study in patients with ED, with or without previ-
ous exposure to PDE5 inhibitors, that documented the
effectiveness and tolerability of tadalafil 5 mg OaD under
routine conditions. The study highlighted that more
than 85 % of men who choose to be treated with tadalafil
OaD maintained the treatment in the next 6 months [20].
In this article, we present results of secondary analyses for
the impact of patient characteristics and relevant comor-
bidities on treatment continuation rates as well as treat-
ment effectiveness and satisfaction in patients with ED
who had started with or switched to tadalafil OaD and
were followed for a period of 6 months.
Methods
Patients and study design
EDATE was a prospective, longitudinal, observational
study conducted in 59 centres across Germany, France,
Italy, and Greece, enrolling patients from November
2011 through June 2012 [20]. Adult male patients who
met the investigator’s criteria for ED and presented
within the normal course of care were eligible to partici-
pate if they had decided, in consultation with their phys-
ician, to either initiate PDE5 inhibitor treatment for the
first time (treatment-naïve) or switch from any previous
PDE5 inhibitor taken on-demand. Patients with previous
experience with tadalafil OaD were excluded. The study
was approved by the Comité de protection des personnes
“Nord-Ouest IV”, centre hospitalier universitaire, faculté
de médecine, pôle recherche, 59045 Lille Cedex, and add-
itional ethical review boards as per individual study site
and country requirements (full list provided as Additional
file 1). Patients provided written informed consent for
data collection, storage, and release of anonymised data.
Assessment and treatment of patients were performed
as per routine investigator practice for managing ED. In
this article, data from patients who initiated or switched
to treatment with tadalafil OaD at baseline (Visit 1) and
were followed up longitudinally for up to 6 months
(tadalafil OaD cohort) are reported. Post-baseline data
were collected at routine visits (Visit 2, Visit 3) within 1
to 3 months and 4 to 6 months after initiation of
therapy. Patients who switched or discontinued tadalafil
OaD treatment during the observation were followed
until the end of the 6-month observation period. A
follow-up phone call was made to patients who did not
visit within 4 to 6 months after baseline.
Outcome measures
The primary results on the time to treatment discon-
tinuation of tadalafil OaD in men who had initiated or
Hatzichristou et al. BMC Urology  (2015) 15:111 Page 2 of 10
switched to tadalafil OaD at baseline have already been
published [20]. The current article includes secondary
outcome results on the impact of patients characteristics
and comorbidities on time to treatment discontinuation,
and on mean changes from baseline to end of observation
in the International Index of Erectile Function (IIEF)
domain scores [21], and Erectile Dysfunction Inventory
for Treatment Satisfaction (EDITS) total score [22].
Statistical analysis
Sample size
A sample size of 250 patients initiating or switching to
tadalafil OaD at baseline was planned, based on the
primary outcome (continuation rate on tadalafil OaD,
estimated to be 50 − 80 % after 6 months of treatment)
[20]. Consecutive enrollment was planned to be stopped
as soon as either 3,000 patients were enrolled overall, or
600 patients were enrolled in the tadalafil OaD cohort.
Primary analysis
All patients prescribed tadalafil OaD treatment at base-
line were included in the analysis. The distribution of
time to discontinuation of tadalafil OaD was estimated
using the Kaplan-Meier product-limit method. The
Kaplan-Meier proportions and associated 95 % confidence
intervals (CIs) of patients on tadalafil OaD at Months 2, 4,
and 6 were reported for the tadalafil OaD cohort (primary
analysis) as well as subgroups stratified by age (18–65
years and >65 years), pretreatment with PDE5 inhibitors,
ED severity (mild, moderate, severe), and presence or
absence of BPH, diabetes, CVD, hypertension, and
dyslipidemia (prespecified subgroup analyses, reported
in this manuscript).
An additional, prespecified exploratory analysis was
performed to investigate the association between time to
discontinuation of tadalafil OaD and selected baseline
factors using a Cox proportional hazards model; hazard
ratios (HRs) and the corresponding 95 %CIs were re-
ported. The final model included factors associated with
treatment discontinuation identified by backward selection
(removing those with p > 0.1). These included presence of
relevant comorbidities, type of physician who initially
diagnosed the ED, country, duration of living arrange-
ment, age, ED etiology, ED severity, and work status [20].
Secondary analyses
All patients prescribed tadalafil OaD at baseline were
included in the longitudinal analyses. Least-square (LS)
mean effects in IIEF domain scores and EDITS total
score from baseline to Month 6 were assessed using a
mixed model for repeated measures (MMRM), including
the following prespecified variables as fixed effects: visit,
age (18–65 vs >65 years), pretreatment with PDE5 inhibi-
tors (yes vs no), etiology of ED, ED severity, BPH (yes vs
no), diabetes (yes vs no), CVD (yes vs no), hypertension
(yes vs no), and dyslipidemia (yes vs no). p-values <0.05
were considered statistically significant and 95 % CIs were
produced. Data were analyzed using the SAS 9.2 software
(SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
Overall, 778 patients received prescriptions for initiating
or switching to tadalafil OaD at baseline. The majority
of patients were aged 18 to 65 years (76.9 %), had suf-
fered from ED for at least 1 year (63.1 %), and presented
with mild to moderate disease at baseline (73.7 %)
(Table 1). Most patients (65.6 %) were naïve to PDE5
inhibitor treatment. Baseline IIEF domain scores were
similar in PDE5 inhibitor-naïve and pretreated patients
(Additional file 2). Over half of the patients (58.4 %) re-
ported having at least 1 comorbid condition. The most
commonly reported comorbidities included CVD (34.5 %),
hypertension (33.4 %), dyslipidemia (18.5 %), and diabetes
(15.9 %). A small proportion of patients reported BPH
(6.3 %) and hypogonadism (1.5 %). Approximately 57.1 %
of the patients were on at least 1 concomitant medication
(Table 1).
Impact of baseline characteristics and comorbidities on
continuation rates of tadalafil OaD
At Month 2, Kaplan-Meier estimation revealed that
more than 90 % of patients were still on tadalafil OaD,
except those aged >65 years (86.7 %) and men with
severe ED (89.0 %) (Table 2). More than 80 % of patients
in all subgroups, except those aged >65 years (75.0 %)
continued tadalafil OaD at Month 6 (Table 2; Additional
file 3). Reasons for discontinuation did not differ notably
between the older (>65 years) and younger age group
(Table 3).
As the majority of patients remained on tadalafil OaD at
Month 6, the median time to discontinuation could not be
estimated in any of the subgroups. Patients with severe
ED had lower treatment continuation rates than those
with mild ED or moderate ED, but these were still >80 %
at all time points (Additional file 4). The Kaplan-Meier
analysis did not suggest any influence of individual comor-
bidities on treatment continuation rates (Table 2).
These findings were consistent with those from the
Cox proportional hazard model evaluating factors associ-
ated with time to discontinuation of tadalafil OaD. The risk
of discontinuation was significantly decreased among youn-
ger vs older patients (HR [95 % CI]: 18–65 vs >65 years:
0.54 [0.30, 0.96], p = 0.038). There was no significant effect
of disease severity (mild vs moderate ED: 1.26 [0.68, 2.32],
p = 0.462; severe vs moderate ED: 1.51 [0.95, 2.39],
p = 0.077), or the presence of relevant comorbidities
(presence vs absence of relevant comorbidities, namely,
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BPH, diabetes, CVD, hypertension, dyslipidemia: 1.27
[0.82, 1.94], p = 0.287) in this model.
Impact of patient characteristics and comorbidities on
erectile function and treatment satisfaction during
treatment with tadalafil OaD
Overall, treatment with tadalafil OaD for 6 months was
associated with significant improvement at Visit 2 (1–3
months) and Visit 3 (4–6 months) in all IIEF domain
scores, including the IIEF-erectile function (EF) domain
(p < 0.001 for both visits), as well as the EDITS total
score (p = 0.035 and p = 0.028 for Visits 2 and 3, respect-
ively) (Table 4). Improvements in the mean (standard
deviation [SD]) IIEF domain scores and EDITS total
score are given in Additional file 5.
MMRM analysis showed that PDE5 pretreatment had a
significantly smaller LS mean effect on IIEF-EF (p < 0.001),
orgasmic function (p = 0.003), intercourse satisfaction
(p = 0.003), and overall satisfaction (p = 0.001) domain
scores vs no previous PDE5 inhibitor treatment. Mild
ED had a significantly smaller LS mean effect on
IIEF-EF (p = 0.011), sexual desire (p = 0.029), and overall
satisfaction (p < 0.001) domain scores, while severe ED
had a significantly increased LS mean effect on the IIEF
orgasmic function (p < 0.001) domain score relative to
moderate ED. The negative effect of BPH on change in
IIEF-EF (p = 0.014), orgasmic function (p = 0.044), and
sexual desire (p = 0.017) domain scores was statistically
significant. Furthermore, diabetes showed a significant
positive effect on changes in IIEF-EF (p = 0.007), orgasmic
function (p = 0.013), intercourse satisfaction (p = 0.030),
and overall satisfaction (p = 0.009) domain scores
(Table 4).
There were no significant effects for age, ED etiology,
CVD, hypertension, or dyslipidemia (p > 0.05 for all
comparisons) on IIEF domain scores over 6 months of
tadalafil OaD treatment. LS mean effects in EDITS total
Table 1 Baseline characteristics of patients starting tadalafil




Median (IQR) 57 (47–65)
18 − 65 years, n (%) 598 (76.9)
Smoking habits, n (%) 775
Current smoker 148 (19.0)
Former smoker 159 (20.4)
Never smoker 468 (60.2)
Currently drink alcohol, n (%) 775 456 (58.8)




Duration of ED symptoms, n (%) 776
< 3 months 55 (7.1)
3 to <12 months 231 (29.7)
≥ 12 months 490 (63.1)





With penile defects, n (%) 776 24 (3.1)
With former invasive diagnostic
procedure for ED, n (%)
776 150 (19.3)
Non-coital erections, n (%) 771 422 (54.7)
Decreased libido, n (%) 775 310 (40.0)
IIEF-EF at baseline, mean (SD) 776 14.5 (7.06)
EDITS total score at baseline, mean (SD) 178a 59.6 (21.27)
Previous treatment, n (%) 777
PDE5 inhibitor pretreated 267 (34.3)
PDE5 inhibitor-naïve 510 (65.6)
Relevant categories of comorbidities, n (%) 778
At least 1 comorbidity 454 (58.4)




Pelvic surgery 89 (11.4)
Benign prostatic hyperplasia 49 (6.3)
Hypogonadism 12 (1.5)
Table 1 Baseline characteristics of patients starting tadalafil
5 mg OaD (N = 778) (Continued)
Concomitant medication, n (%) 778
At least 1 concomitant medication 444 (57.1)
Antihypertensive medication 260 (33.4)
Lipid lowering medication 152 (19.5)
Oral antidiabetic medication 102 (13.1)
Cardiovascular medication 94 (12.1)
α-blockers 58 (7.5)
5α-reductase inhibitors 14 (1.8)
ED, erectile dysfunction, EDITS Erectile Dysfunction Inventory of Treatment
Satisfaction, IIEF-EF International Index of Erectile Function-Erectile Function,
IQR inter quartile range, N number of patients with data, n number of patients,
OaD once a day, PDE5 phosphodiesterase type 5, SD standard deviation
aEDITS scores at baseline were collected only in patients pretreated with
PDE5 inhibitors
Hatzichristou et al. BMC Urology  (2015) 15:111 Page 4 of 10
score were not affected by any comorbidity or baseline
characteristic except age (p = 0.008) (Table 4).
Safety
No treatment-related serious adverse events were re-
ported during the study. The most frequently reported
adverse events included headache (1.3 %), dyspepsia
(0.5 %), and a new diagnosis of BPH (0.5 %); no new or
unexpected safety signals were observed [20].
Discussion
Currently, there are few observational studies in patients
with ED that assess the impact of baseline characteristics
and presence of comorbid conditions on PDE5 inhibitor
treatment continuation rates. In particular, few existing
studies assess treatment satisfaction and effectiveness
beyond the IIEF-EF domain. The primary analysis of the
EDATE observational study demonstrated high treatment
continuation rates (86.3 %) over a period of 6 months in
778 patients with ED who initiated or switched to
PDE5 inhibitor treatment with tadalafil OaD at base-
line (Additional file 6) [20].
Here in this cohort with high frequency of comorbidi-
ties and use of concomitant medications, we found that
continuation rates over 6 months of treatment with
tadalafil OaD were comparable across subgroups. Fur-
thermore, continuation rates were over 80 % regardless
of the presence of comorbidities, pretreatment with
PDE5 inhibitors, or ED severity. Even in the subgroup of
older patients (>65 years), the continuation rate was
75 % at Month 6. IIEF was affected by some baseline
characteristics including ED severity, pretreatment with
Table 2 Impact of patient characteristics and comorbidities on the continuation of treatment with tadalafil 5 mg OaD (N = 778)
Population Number of patients with Patients without events (%), KM estimate [95 % CI]
Data Events Month 2 Month 4 Month 6
Overall (primary analysis) 773 107 94.0 [92.3,95.7] 88.3 [85.9,90.6] 86.3 [83.7,88.9]
By age
Age ≤65 years 593 61 96.2 [94.7,97.8] 91.7 [89.4,93.9] 89.8 [87.1,92.4]
Age >65 years 180 46 86.7 [81.7,91.6] 77.3 [71.1,83.5] 75.0 [68.5, 81.5]
By PDE5-I treatment
PDE5-I naïve 507 71 93.9 [91.8,96.0] 88.5 [85.7,91.4] 86.1 [82.9,89.4]
PDE5-I pretreated 265 36 94.2 [91.4,97.1] 87.6 [83.6,91.7] 86.6 [82.3,90.9]
By disease severity
Mild ED 160 16 98.1 [96.0,1.00] 94.1 [90.3,97.8] 89.8 [84.4,95.3]
Moderate ED 407 55 94.8 [92.7,97.0] 88.6 [85.5,91.8] 87.3 [83.9,90.8]
Severe ED 203 36 89.0 [84.6,93.3] 82.8 [77.4,88.2] 80.8 [75.1,86.5]
By presence of BPH
BPH present 49 10 91.8 [84.2,99.5] 87.8 [78.6,96.9] 84.9 [74.5,95.3]
BPH absent 724 97 94.1 [92.4,95.9] 88.3 [85.9,90.7] 86.4 [83.7,89.1]
By presence of diabetes
Diabetes present 123 19 93.4 [88.9,97.8] 85.3 [78.9,91.8] 84.0 [77.2,90.9]
Diabetes absent 650 88 94.1 [92.3,95.9] 88.8 [86.3,91.3] 86.7 [83.9, 89.5]
By presence of CVD
CVD present 266 41 90.9 [87.4,94.4] 86.8 [82.7,91.0] 84.6 [80.1,89.2]
CVD absent 507 66 95.6 [93.8,97.4] 89.0 [86.2,91.8] 87.2 [84.0,90.3]
By presence of hypertension
Hypertension present 258 40 91.0 [87.5,94.5] 86.8 [82.6,91.0] 84.6 [79.9,89.2]
Hypertension absent 515 67 95.5 [93.7,97.3] 89.0 [86.2,91.8] 87.2 [84.0,90.3]
By presence of dyslipidemia
Dyslipidemia present 144 24 91.6 [87.0,96.1] 86.3 [80.6,92.1] 83.5 [77.2,89.9]
Dyslipidemia absent 629 83 94.5 [92.8,96.3] 88.7 [86.2,91.2] 87.0 [84.2,89.8]
Event = Discontinuation of tadalafil OaD
Note: KM estimates for subgroups with non-overlapping CIs at given time points are marked in bold
BPH benign prostatic hyperplasia, CI confidence interval, CVD cardiovascular diseases, ED erectile dysfunction, KM Kaplan-Meier, N number of patients, OaD once a
day, PDE5-I phosphodiesterase type 5 inhibitor
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PDE5 inhibitors, and the presence or absence of diabetes
and BPH. However, treatment satisfaction remained pre-
dominantly unaffected by any comorbid condition or
baseline characteristic except for age, with patients aged
18–65 years reporting significantly higher satisfaction
scores vs those aged >65 years.
In our study, younger patients (18–65 years) had
higher chances of continuing tadalafil OaD vs older pa-
tients. This finding resonates with that from the DE-
TECT observational study in which age less than
60 years was one of the factors associated with continu-
ation of tadalafil on-demand treatment at 12 months
[23]. Similarly, an observational study in Latin America
found that persistence and adherence rates for PDE5
inhibitor treatment at 6 months were generally higher in
younger men with ED (mean age, 52.3 years vs 54.9 years
for non-persistent patients and 52.1 years vs 55.5 years
for non-adherent patients) [24]. In a Korean study, the
most common reason for discontinuing PDE5 inhibitor
treatment given by older men (>70 years) with ED was
concerns about the side effects, possibly due to higher
prevalence of comorbidities in this subgroup [25].
We observed significant improvement from baseline in
all the IIEF domain scores and EDITS total score at the
second (1–3 months) and third (4–6 months) visits in
the overall tadalafil OaD cohort. In particular, the LS
mean IIEF-EF domain score increased by 7.1 points from
baseline to 4 to 6 months after initiation of tadalafil
OaD, exceeding the minimal clinically important differ-
ence (MCID) of 4 points [26]; this observation aligns
with the 9.4-point increase observed with tadalafil OaD
in a previous randomised controlled trial [27].
We found that PDE5 inhibitor pretreatment had a sig-
nificant impact on IIEF scores, i.e. pretreated patients
showed less improvement during tadalafil OaD treat-
ment compared with treatment-naïve patients, in the do-
mains of EF, orgasmic function, intercourse satisfaction,
and overall satisfaction. In the EDATE cohort, 36.7 % of
patients switched to tadalafil OaD due to lack of efficacy
of previous PDE5 inhibitor treatment [20]. Thus, we
believe that some of the patients in the tadalafil OaD
cohort who were pretreated with PDE5 inhibitors may
have been insufficient responders to any PDE5 inhibitor
treatment, leading to a negative effect on their IIEF
domain scores. In real-life clinical practice, men with
inadequate response to ED treatment will usually keep
seeking for a better treatment option to improve their
erection. A large observational study in Middle Eastern
countries among men with ED receiving tadalafil on-
demand (N = 1,080) also found significantly higher mean
IIEF-EF domain scores in treatment-naïve patients vs
those who were pretreated (13.26 vs 9.28; p < 0.0001) [28].
ED etiology had no significant effect on IIEF in our
study. This is in keeping with findings from an inte-
grated analysis of 6 randomised studies which showed
that tadalafil OaD was consistently efficacious across
disease etiologies in men with ED [29].
In this study, there were significant effects of ED se-
verity on the IIEF-EF, orgasmic function, sexual desire,
and overall satisfaction domains. Mild ED reduced the
change from baseline for IIEF-EF, sexual desire, and
overall satisfaction, while severe ED meant an increased
change in orgasmic function relative to moderate ED.
This aligns with findings from an analysis of 6
Table 3 Reasons for discontinuation of tadalafil OaD treatment by age group
Number (%) of patients
Age ≤65 years N = 598 Age >65 years N = 180 Overall N = 778
Discontinued tadalafil OaDa 61 (100.0) 46 (100.0) 107 (100.0)
Reasons
Lack of efficacy (hardness of erection) 17 (27.9) 16 (34.4) 33 (30.8)
Adverse event 10 (22.5) 12 (26.1) 22 (20.6)
Cost of medication 11 (18.0) 5 (10.9) 16 (15.0)
Didn’t want to take a pill every day 7 (11.0) 5 (10.9) 12 (11.2)
Patient discontinued study 7 (11.5) 2 (4.3) 9 (8.4)
Partner’s request 2 (3.3) 3 (6.5) 5 (4.7)
Felt that medication controlled his sexual life 2 (4.2) 1 (2.2) 3 (2.8)
Slow onset of action 2 (3.3) 1 (2.2) 3 (2.8)
Lack of efficacy (duration of erection) 1 (1.6) 1 (2.2) 2 (1.9)
Lack of confidence in medication 1 (1.6) 0 1 (0.9)
Non-desired spontaneous erections 1 (1.6) 0 1 (0.9)
N number of patients, OaD once a day
aIncludes all patients with documented end date of tadalafil OaD treatment, irrespective if the patient completed or discontinued the study
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Table 4 Impact of patient-characteristics and comorbidities on EF and treatment-satisfaction during tadalafil OaD treatment
(N = 778; MMRM)
IIEF domain scores (n = 646) EDITS total
score (n = 165)aErectile function Orgasmic function Sexual desire Intercourse satisfaction Overall satisfaction
Change from baseline at Visit 2
LS mean +6.17* +1.06* +0.38* +2.70* +2.26* +14.17*
95 % CI +4.82 to +7.51 +0.54 to +1.57 +0.03 to +0.74 +2.02 to +3.38 +1.77 to +2.75 +1.00 to +27.34
p-value <0.001 <0.001 0.034 <0.001 <0.001 0.035
Change from baseline at Visit 3
LS mean +7.11* +1.36* +0.48* +3.18* +2.56* +14.83*
95 % CI +5.76 to +8.47 +0.83 to +1.88 +0.12 to +0.84 +2.48 to +3.87 +2.06 to +3.06 +1.64 to +28.02
p-value <0.001 <0.001 0.010 <0.001 <0.001 0.028
Fixed effects
Age group (18–65 vs >65 years)
LS mean effect +0.45 −0.11 +0.15 +0.20 +0.04 +11.25*
95 % CI −0.98 to +1.88 −0.66 to +0.44 −0.23 to +0.53 −0.53 to +0.92 −0.49 to +0.56 +2.96 to +19.54
p-value 0.539 0.707 0.444 0.592 0.896 0.008
PDE5-I pretreatment (yes vs no)
LS mean effect −2.13* −0.69* −0.10 −0.93* −0.74* +7.11
95 % CI −3.33 to −0.94 −1.15 to −0.23 −0.41 to +0.22 −1.54 to −0.33 −1.17 to −0.30 −12.5 to +26.74
p-value <0.001 0.003 0.548 0.003 0.001 0.475
ED etiology
Psychogenic vs mixed
LS mean effect −0.25 +0.17 +0.04 −0.03 +0.06 −4.69
95 % CI −1.75 to +1.26 −0.41 to +0.75 −0.35 to +0.44 −0.79 to +0.74 −0.49 to +0.62 −15.2 to +5.79
p-value 0.747 0.558 0.825 0.944 0.817 0.378
Organic vs mixed
LS mean effect −0.63 −0.17 −0.13 −0.44 −0.39 −1.70
95 % CI −1.97 to +0.71 −0.69 to +0.34 −0.48 to +0.23 −1.12 to +0.24 −0.88 to +0.10 −9.31 to +5.92
p-value 0.359 0.507 0.479 0.205 0.116 0.661
ED severity (investigator assessment)
Mild vs moderate
LS mean effect −2.00* −0.06 −0.45* −0.56 −0.97* −4.52
95 % CI −3.54 to −0.46 −0.66 to +0.53 −0.86 to −0.05 −1.35 to +0.22 −1.53 to −0.41 −16.4 to +7.35
p-value 0.011 0.833 0.029 0.156 <0.001 0.453
Severe vs moderate
LS mean effect +0.99 +0.93* −0.21 +0.30 +0.30 +3.99
95 % CI −0.37 to +2.34 +0.41 to +1.45 −0.57 to +0.15 −0.39 to +0.99 −0.20 to +0.80 −3.37 to +11.35
p-value 0.154 <0.001 0.260 0.395 0.237 0.285
Comorbidities
BPH (yes vs no)
LS mean effect −2.77* −0.87* −0.72* −1.08 −0.52 +5.78
95 % CI −4.98 to −0.55 −1.73 to −0.02 −1.30 to −0.13 −2.21 to +0.04 −1.34 to +0.29 −8.38 to +19.94
p-value 0.014 0.044 0.017 0.058 0.206 0.421
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randomised studies of tadalafil 2.5 and 5 mg OaD in
patients with ED. Placebo-adjusted LS mean changes in
IIEF-EF from baseline for both doses of tadalafil were
numerically higher in patients with severe ED (4.6 and
5.8) vs those in patients with mild (2.3 and 4.5) and
moderate (4.4 and 5.5) ED [29]. This may be explained
by the possibility of greater changes from baseline in
patients with more severe disease compared with those
with mild or moderate disease. Furthermore, Rosen and
colleagues have demonstrated that the MCID in the
IIEF-EF domain increases significantly with higher base-
line severity of ED (p < 0.0001) [26].
We observed a significant impact of reported BPH on
IIEF-EF, orgasmic function, and sexual desire domain
scores, i.e., the presence of BPH reduced improvement
during tadalafil OaD treatment. However, BPH can be
accompanied by other comorbidities and the estimated
reduction in efficacy from our model is unlikely to de-
fine the differences between BPH and non-BPH patients
alone. It is worth noting that patients with BPH in our
study did show improvement from baseline to Month 6
in unadjusted mean (SD) IIEF-EF domain score (5.7 [6.7]);
Additional file 5). However, self-reported prevalence
of BPH was small (6.3 %), and a full baseline assessment
of LUTS/BPH was not actively performed. Thus, our
findings in the small number of patients with BPH
should be interpreted with caution.
In our study, diabetes significantly impacted the
changes in IIEF domains of EF, orgasmic function, inter-
course satisfaction, and overall satisfaction, i.e., patients
with diabetes showed more improvement than patients
without diabetes. This may have occurred because pa-
tients with diabetes had more severe ED at baseline.
According to the MALES study, men with diabetes were
more likely to perceive their ED to be severe and per-
manent vs those without diabetes [30]. The efficacy of
tadalafil OaD for ED treatment in males with diabetes
has been previously evaluated in a placebo controlled,
randomised multicentre study, showing statistically signifi-
cant improvements in the IIEF-EF (p ≤ 0.005), intercourse
satisfaction (p = 0.033), and overall satisfaction (p < 0.001)
domain scores vs placebo [31].
There was no significant effect of CVD, dyslipidemia,
and hypertension on any of the IIEF domain scores,
similar to results from previous studies. In an integrated
analysis of data from 6 randomised controlled trials, pa-
tients with ED receiving tadalafil 2.5 and 5 mg OaD ex-
perienced IIEF-EF LS mean improvements reaching or
exceeding the MCID (≥4) regardless of CVD, diabetes,
hypertension, or hyperlipidemia [29]. Furthermore, in an
analysis of 11 placebo-controlled randomised studies,
tadalafil on-demand significantly improved IIEF-EF domain
score from baseline (p < 0.005 vs placebo) in all subpopula-
tions regardless of age, disease etiology, severity and
Table 4 Impact of patient-characteristics and comorbidities on EF and treatment-satisfaction during tadalafil OaD treatment
(N = 778; MMRM) (Continued)
Diabetes (yes vs no)
LS mean effect +2.28* +0.81* +0.06 +0.92* +0.81* +5.62
95 % CI +0.64 to +3.92 +0.17 to +1.44 −0.38 to +0.50 +0.09 to +1.76 +0.20 to +1.41 −3.62 to +14.71
p-value 0.007 0.013 0.787 0.030 0.009 0.223
CVD (yes vs no)
LS mean effect −1.78 −1.93 0 −0.97 −0.49 +3.48
95 % CI −7.53 to +3.96 −4.14 to +0.29 −1.52 to +1.52 −3.88 to +1.95 −2.60 to +1.62 −2.70 to +33.97
p-value 0.542 0.088 0.997 0.515 0.648 0.822
Hypertension (yes vs no)
LS mean effect +1.62 +1.91 +0.29 +0.77 −0.04 −1.33
95 % CI −4.14 to +7.39 −0.31 to +4.13 −1.24 to +1.81 −2.16 to +3.69 −2.15 to +2.07 −31.7 to +29.00
p-value 0.580 0.091 0.711 0.606 0.969 0.931
Dyslipidemia (yes vs no)
LS mean effect −0.05 −0.19 −0.31 +0.02 −0.17 −4.26
95 % CI −1.61 to +1.51 −0.79 to +0.41 −0.72 to +0.11 −0.78 to +0.81 −0.74 to +0.41 −13.1 to +4.60
p-value 0.946 0.528 0.145 0.966 0.568 0.343
BPH benign prostatic hyperplasia, CI confidence interval, CVD cardiovascular disease, ED erectile dysfunction, EDITS Erectile Dysfunction Inventory of Treatment
Satisfaction, IIEF International Index of Erectile Function, LS mean least-square mean, MMRM Mixed Model for Repeated Measures, N number of patients, n number
of patients included in the model, OaD once a day, PDE5-I phosphodiesterase type 5 inhibitor
aEDITS scores at baseline were collected only in patients pretreated with PDE5-I
*95 % confidence interval does not include zero and p-value statistically significant (<0.05)
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duration, and presence of comorbid conditions such
as diabetes, hypertension, CVD, hyperlipidemia, depression,
and BPH [32].
Treatment satisfaction, as assessed by EDITS, was not
affected by pretreatment with PDE5 inhibitors, ED eti-
ology, ED severity, or presence of relevant comorbidities
in this study. This is consistent with data from a previous
randomised study in which patients receiving fixed-dose
tadalafil on-demand were significantly more satisfied with
their treatment vs placebo (p < 0.001) despite high inci-
dence of severe, organic ED and presence of comorbid
conditions [33].
Large overall sample size, longitudinal nature, real life
setting, and including patients with ED from several
countries were important strengths of this study. In
addition, to increase the external validity of the study,
study sites were selected randomly from a list of investi-
gators who expressed interest in participation and by
asking sites to enroll patients consecutively. However,
results may still be biased as only sites and investigators
with interest were selected. As patients had to pay for
their treatment, the study may also be biased towards
those with higher education and economic status. The
prevalence of comorbidities was based on patient-reported
data, and was not confirmed by active baseline assessment
by investigators. Thus, results may have been biased by false
positive or missed diagnoses, and should be interpreted
with caution.
Being an observational study, the patient population
within subgroups was not well-defined. The small num-
ber of discontinuation events additionally limits the sub-
group analysis of time to discontinuation. Nevertheless,
this study provides valuable data on the impact of base-
line characteristics and presence of comorbidities on
continuation rates, and effectiveness and satisfaction of
treatment with tadalafil OaD in a naturalistic setting and
therefore has implications for everyday clinical practice.
Furthermore, ED and CVD have common pathogenic
pathways mediated via endothelial dysfunction [34], and
it is suggested that tadalafil may potentially provide
beneficial effects in patients with coronary artery disease,
hypertension, heart failure, pulmonary arterial hyperten-
sion, diabetes mellitus, and Raynaud’s phenomenon [35].
Conclusions
This observational study found that under routine clin-
ical conditions, the presence of comorbidities did not
have any significant impact on treatment continuation
rates and treatment satisfaction among men with ED
who choose treatment with tadalafil OaD. Continuation
rates and treatment satisfaction were comparatively
lower in men older than 65 years. Pretreatment with
PDE5 inhibitors, ED severity, and presence or absence
of diabetes and BPH had an impact on treatment
effectiveness; however, age and presence of hypertension,
CVD, dyslipidemia, or ED etiology did not affect IIEF in
this cohort. These findings have clinical implications for
counseling patients with ED, particularly for discussing ex-
pectations after PDE5 inhibitor treatment, as comorbidi-
ties are common in these patients, especially in older men.
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